Healthtech Series B Investors & VC Firms
1027 firms in this list, with a median first check of $540K. 256 of them lead rounds. Generated from verified public data and updated continuously.
Heliad AG
Frankfurt am MainPre-Seed–Late Stage$5.4M – $16.2M
14 people
Quadrille Capital
ParisSeed–Late Stage
15 people
Town Hall Ventures
New YorkPre-Seed–Late Stage$3M – $30M
3 people
Sodero
NantesSeed–Late Stage$162K – $5.4M
19 people
6 Dimensions Capital
Grand CaymanSeed–Late Stage
17 people
CTI Life Sciences Fund L.P.
MontréalSeed–Late Stage
9 people
GSR United Capital
BeijingSeed–Growth
Peak State Ventures
New YorkPre-Seed–Late Stage$100K – $15M
1 person
Smilegate Investment
SeoulSeed–Series B$500K
15 people
359 Capital
New York CitySeed–Series C
10 people
Velvet Sea Ventures
West Palm BeachSeed–Growth
10 people
LifeSci Venture Partners
New YorkSeries A–Series C
6 people
Mérieux Equity Partners
ParisSeed–Growth$3.2M – $86M
14 people
Tenmile
Seed–Series B
11 people
Tamarind Hill
DublinPre-Seed–Series B$2M – $7M
9 people
Westerly Winds
LondonPre-Seed–Series B
17 people
Expon Capital
LuxembourgSeed–Growth$550K – $1.6M
5 people
Iter Investments
South FloridaSeed–Series B
14 people
VentureWave Capital Ltd.
DublinSeries A–Series B
21 people
Wittington Ventures
TorontoSeed–Growth
12 people
Scientia Ventures
New YorkSeries A–Series B
13 people
OWW Capital Partners Pte. Ltd.
SingaporeSeed–Late Stage$500K – $10M
9 people
Fund+
LeuvenSeries A–Series B$5.5M – $16.5M
11 people
Bridge Bank
San FranciscoSeed–Late Stage
16 people
Related lists
Healthtech Investors & VC Firms (4190)Healthtech Seed Investors & VC Firms (3233)Series B Investors & VC Firms (2946)Healthtech Investors & VC Firms in North America (2665)Healthtech Investors & VC Firms in United States (2436)Healthtech Series A Investors & VC Firms (2309)Series B Investors & VC Firms in North America (1736)Series B Investors & VC Firms in United States (1571)Healthtech Pre-Seed Investors & VC Firms (1468)Healthtech Investors & VC Firms in Europe (1357)
Data sourced from public filings and firms' own websites — see our methodology.

































































































